Literature DB >> 8420443

Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.

G B McDonald1, M S Hinds, L D Fisher, H G Schoch, J L Wolford, M Banaji, B J Hardin, H M Shulman, R A Clift.   

Abstract

OBJECTIVE: To determine the incidence and clinical course of veno-occlusive disease of the liver (VOD) after bone marrow transplantation and to analyze risk factors for severe VOD.
DESIGN: Cohort study of 355 consecutive patients.
SETTING: A bone marrow transplantation center. MEASUREMENTS: Each patient was prospectively evaluated for VOD, and many risk factors for severe VOD were analyzed using logistic regression models. The relation of VOD to renal and cardiopulmonary failure was analyzed using time-dependent proportional hazards models.
RESULTS: Veno-occlusive disease developed in 190 of 355 patients (54%; 95% CI, 48% to 59%): Fifty-four patients had severe VOD and 136 had mild or moderate VOD. Independent variables derived from a multivariate model for predicting severe VOD included elevated transaminase values before transplantation (relative risk, 4.6; P < 0.0001); vancomycin therapy during cytoreductive therapy (relative risk, 2.9; P = 0.003); cytoreductive therapy with a high-dose regimen (relative risk, 2.8; P = 0.01); acyclovir therapy before transplantation (relative risk, 4.8; P = 0.02); mismatched or unrelated donor marrow (relative risk, 2.4; P = 0.02); and previous radiation therapy to the abdomen (relative risk, 2.2; P = 0.04). Vancomycin therapy was a marker for persistent fever. Multiorgan failure was more frequent among patients with VOD and usually followed the onset of liver disease.
CONCLUSIONS: Veno-occlusive disease, which developed in 54% of bone marrow transplant recipients, is frequently associated with renal and cardiopulmonary failure. Pretransplant transaminase elevations, use of high-dose cytoreductive therapy, and persistent fever during cytoreductive therapy are independent predictors of severe VOD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8420443     DOI: 10.7326/0003-4819-118-4-199302150-00003

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  193 in total

1.  Irradiation induces homing of donor endothelial progenitor cells in allogeneic hematopoietic stem cell transplantation.

Authors:  Lingyu Zeng; Shuang Ding; Zhiling Yan; Chong Chen; Wei Sang; Jiang Cao; Hai Cheng; Kailin Xu
Journal:  Int J Hematol       Date:  2012-01-19       Impact factor: 2.490

2.  LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.

Authors:  Navin Khattry; Alok Gupta; Reetu Jain; Adwaita Gore; Ravi Thippeswamy; Nandish Jeevangi; Sadhana Kannan; Reena Nair; Tapan Saikia
Journal:  Int J Hematol       Date:  2016-01-04       Impact factor: 2.490

Review 3.  Acute kidney injury in HCT: an update.

Authors:  J A Lopes; S Jorge; M Neves
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

4.  Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease.

Authors:  Brandon M Triplett; Hani I Kuttab; Guolian Kang; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-14       Impact factor: 5.742

5.  Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.

Authors:  Janka Reimer; Sandra Bien; Sabine Ameling; Elke Hammer; Uwe Völker; Georg Hempel; Joachim Boos; Heyo K Kroemer; Christoph A Ritter
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

6.  Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant.

Authors:  Rish K Pai; Koen van Besien; John Hart; Andrew S Artz; Peter H O'Donnell
Journal:  Leuk Lymphoma       Date:  2012-03-13

7.  Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children.

Authors:  M Philippe; S Goutelle; J Guitton; X Fonrose; C Bergeron; P Girard; Y Bertrand; N Bleyzac
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

8.  Diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome of the liver: problems of interpretation.

Authors:  L Volin; R Niittyvuopio; J Heiskanen; V Lindström; A Nihtinen; L Sahlstedt; T Ruutu
Journal:  Bone Marrow Transplant       Date:  2016-09-26       Impact factor: 5.483

Review 9.  Vascular liver diseases.

Authors:  Laurie D DeLeve
Journal:  Curr Gastroenterol Rep       Date:  2003-02

10.  Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Authors:  Carlos A Ramos; Rima M Saliba; Leandro de Pádua; Ola Khorshid; Elizabeth J Shpall; Sergio Giralt; Poliana A Patah; Chitra M Hosing; Uday R Popat; Gabriela Rondon; Issa F Khouri; Yago L Nieto; Richard E Champlin; Marcos de Lima
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.